
Alkem launches breast cancer biosimilar in India
Alkem Laboratories on Monday said it has launched a biosimilar product in India for the treatment of breast cancer. The company has introduced Pertuza injection 420mg/14mL, a pertuzumab biosimilar, for the treatment of HER2-positive breast cancer, the drug firm said in a statement. Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab, it…